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Abstract
Purpose This observational study was designed to measure baseline energy parameters and body composition in early-stage 
breast cancer patients, and to follow changes during and after various modalities of treatment. This will provide information 
to aid in the development of individualized physical activity intervention strategies.
Methods Patients with newly diagnosed stage 0–III breast cancer were enrolled into three cohorts: A (local therapy alone), B 
(endocrine therapy), or C (chemotherapy with or without endocrine therapy). At baseline, 6 months, and 12 months, subjects 
underwent a stationary bicycle protocol to assess power generation and DEXA to assess body composition.
Results Eighty-three patients enrolled. Patients had low and variable levels of power generation at baseline (mean power 
per kilogram lean mass 1.55 W/kg, SD 0.88). Power normalized to lean body mass (W/kg) decreased significantly, and simi-
larly, by 6 months in cohorts B (1.42–1.04 W/kg, p = 0.008) and C (1.53–1.18 W/kg, p < 0.001). In all cohorts, there was no 
recovery of power generation by 12 months. Cohort C lost lean body mass (− 1.5 kg, p = 0.007), while cohort B maintained 
lean body mass (− 0.2 kg, p = 0.68), despite a similar trajectory in loss of power. Seven patients developed sarcopenia during 
the study period, including four patients who did not receive any chemotherapy (cohort B).
Conclusions The stationary bike protocol was feasible, easy, and acceptable to patients as a way to measure energetic capac-
ity in a clinical setting. Early-stage breast cancer patients had low and variable levels of power generation, which worsened 
following primary therapy and did not show evidence of ‘spontaneous recovery’ by 12 months. Effective physical activity 
interventions will need to be personalized, accounting for both baseline ability and the effect of treatment.
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Background
An accumulating body of evidence supports an associa-
tion between physical activity and improved quality of life, 
overall health, and disease-related outcomes for millions 
of breast cancer survivors. A large meta-analysis of obser-
vational studies found a significantly decreased risk of all-
cause and breast cancer-specific mortality for survivors par-
ticipating in higher levels of post-diagnosis physical activity, 
compared with lower levels (HR 0.52, 95% CI 0.43–0.64, 
p < 0.01; and HR 0.59, 95% CI 0.45–0.78, p < 0.05, respec-
tively) [1]. Unfortunately, the majority of breast cancer 
survivors are physically inactive and self-report stable or 
decreased physical activity levels following diagnosis [2, 3].
Exercise intervention trials for breast cancer survivors are 
feasible and result in beneficial effects on body composition, 
fitness, fatigue, and quality of life [4, 5]. However, only a 
fraction of eligible patients agree to participate and even 
fewer complete the prescribed intervention, limiting the gen-
eralizability of these interventions. Patients who report more 
fatigue or who have limited prior exercise experience are 
less likely to participate or comply; consequently the precise 
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population in greatest need is the least likely to benefit from 
current approaches [6–8].
Breast cancer patients, like the general population, 
have variable levels of exercise capacity both at the time 
of diagnosis and post- treatment. Although generic, pop-
ulation-based guidelines for physical activity in cancer 
survivors exist, these are not well defined and are not tai-
lored to a patient’s starting exercise capacity [9].Too often, 
these guidelines may not be initially achievable for indi-
vidual breast cancer patients, leading to frustration, injury, 
early discontinuation, or opting out of exercise interven-
tions entirely. In addition, while patients may subjectively 
describe fatigue or weakness, clinically feasible objective 
measures of exercise capacity to guide interventions and 
construct individualized recommendations are lacking.
This observational study was conducted to provide the 
foundational data needed to develop individualized physical 
activity intervention strategies for early-stage breast cancer 
patients. We sought to measure baseline energy param-
eters and body composition, and to follow changes in those 
parameters during treatment. Evaluation 1 year from diag-
nosis was included to assess ‘spontaneous recovery’ after 
finishing treatment.
Methods
Study population
This prospective study enrolled patients with newly diag-
nosed ductal carcinoma in situ (DCIS) or stage I–III invasive 
breast cancer presenting to the Indiana University Melvin 
and Bren Simon Cancer Center and Eskenazi Health in Indi-
anapolis, Indiana. Eligible patients had not yet initiated any 
therapy for their breast cancer and had no neurologic, ortho-
pedic, cardiac, or pulmonary conditions that would interfere 
with the ability to complete the stationary bicycle protocol. 
Patients were enrolled into one of the three cohorts based 
on planned therapy: cohort A included patients who would 
receive local therapy alone (surgery ± radiation therapy), 
cohort B included patients planned to receive local therapy 
with anti-estrogen therapy as the sole systemic treatment, 
and cohort C included patients planned to receive local 
therapy and chemotherapy with or without anti-estrogen 
treatment. Planned treatment was indicated at the time of 
study registration. Patients registered to cohorts A and B 
who received chemotherapy based on findings at the time 
of surgery were transferred to and analyzed with cohort C. 
Patients were compensated for the time required to complete 
the study assessments. The IU Institutional Review Board 
approved the study and patients provided written informed 
consent prior to participation. Research has been performed 
in accordance with the ethical standards of the Declaration 
of Helsinki.
Study design
Energetic capacity
The primary objective was to establish energetic capacity. 
Ten seconds mean peak watts (watts) and watts per kilo-
gram (kg) of lean body mass (watts/kg) of newly diagnosed 
breast cancer patients were recorded at baseline and at 6- and 
12-month post-diagnosis. We quantified energetic capacity 
using the Power Protocol-B™, a stationary bicycle-based 
procedure that establishes the range of motive power perfor-
mance of the patient (termed “power envelope”). The Power 
Protocol-B™ is less invasive, costly, intimidating, and tech-
nically difficult than other standard measures of fitness, such 
as maximal  VO2, and can be performed in an ambulatory 
clinic setting [10]. Measures obtained from Power Protocol-
B™ include, but are not limited to, minimal and maximal 
power production, sustained power at a given heart rate, 
and heart rate separation zone, which is one indicator of 
anaerobic threshold. Importantly, data generated from Power 
Protocol-B™ are independent of patient effort over a wide 
range of ability.
Power Protocol-B™ testing was conducted on a Saris 
CycleOps 400 Pro stationary bicycle (Saris cycling Group, 
Fitchburg, WI) incorporating a 45-pound flywheel to smooth 
power pulses from rider impulses to the cranks. PowerTap 
resistive strain gauge sensors in the wheel measure power 
(watts) with a validated accuracy and linearity of 98.5% 
[11]. The 400 Pro is equipped with a wireless central pro-
cessing unit (CPU), a wireless heart rate strap (recording 
directly to an integrated data file in the CPU), and a config-
urable display set to display power, cadence, derived speed, 
heart rate, and elapsed time. The bicycle readily accommo-
dates a wide variety of body types; patients were individu-
ally fit before the initial assessment using accepted biody-
namic fit procedures. Patients wore chest mounted, medical 
grade heart rate monitors during testing. Heart rates were 
recorded by a central CPU and continuously observed by 
study staff. After an initial 5-min warm-up period, power 
demands were increased every 3 min until one of the fol-
lowing conditions was reached: heart rate ≥ 180 bpm, patient 
could no longer turn the cranks, patient stood on the cranks, 
or patient reported exhaustion and a desire to stop. Assess-
ments were performed at baseline (prior to any local or sys-
temic therapy), 6 months, and 12 months after enrollment.
Body composition
A secondary objective was to explore the relationship of 
energetic capacity to body mass index (BMI) and body 
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composition. Dual resistant X-ray absorptiometry (DEXA) 
was used to measure total body composition, including BMI, 
total lean body mass, appendicular lean mass, and percent-
age of body fat at baseline, 6 months, and 12 months fol-
lowing enrollment. Skeletal muscle index (SMI) was calcu-
lated as the appendicular lean mass in kilograms divided by 
height squared. Given its important association with reduced 
survival in several solid tumor populations [12], sarcopenia 
incidence was calculated for each cohort and defined as SMI 
two standard deviations below young adult female popula-
tion norms (< 5.45 kg/m2) [13].
Statistical analysis
This longitudinal cohort pilot study quantified the impact of 
breast cancer therapy on energetic capacity as measured by 
power generation. Sample size was determined by feasibility 
and precision around the estimates needed to design further 
studies. A minimum of 12 patients per group were needed; 
to account for drop-outs and missing data, and to increase 
precision around the estimates, we planned to enroll of up to 
28 patients per cohort. The primary endpoints were changes 
in power per kilogram of lean body mass and mean peak 
watts over 10 s expended during the Power Protocol™ test 
between time points with T-tests to determine significance at 
the 0.05 level. Spearman’s correlations were used to evaluate 
the relationship between power and BMI, lean body mass, 
body fat percentage, and SMI.
Results
Patient characteristics
A total of 83 eligible patients were enrolled (Fig. 1). One 
patient was found to have renal cell carcinoma and two oth-
ers withdrew during screening prior to the baseline assess-
ments. Eighty patients completed at least one assessment 
and thus were evaluable. Six patients initially enrolled 
to cohort A or B were transferred to cohort C when final 
pathology dictated the need for chemotherapy. Final analysis 
is based on 15 patients in cohort A, 33 in cohort B, and 32 
in cohort C.
Four patients withdrew prior to the 6-month time point 
and 2 prior to the 12- month assessment. Overall, 74 patients 
(93%) completed all planned PowerProtocol™ assessments. 
All patients were female. Median age was 55; patients who 
received chemotherapy (cohort C) tended to be slightly 
younger. Most (44%) had stage I disease. Nearly half of 
patients receiving chemotherapy also received anti-estrogen 
treatment (Table 1).
Fig. 1  Consort diagram
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Power generation
In the total study population, patients were deconditioned 
at baseline with power generation of 62.7  watts (SD 
32.96 watts). There was no difference in power generation 
between the cohorts at baseline. The apparent higher level 
of baseline power in Cohort A (A: 74.9 watts, B: 56.5 watts, 
C: 63.0 watts) did not reach significance (p = 0.241). In the 
total population, power decreased at 6 months (62.7 vs. 
48.2 watts; p < 0.001) and did not significantly recover at 
12 months (48.2 vs. 49 watts; p = 0.978). At 6 months, power 
output dropped significantly in the cohorts receiving endo-
crine therapy (B: 56.5–42.11 watts, p = 0.003) and chemo-
therapy (C: 63.6–46.6 watts, p < 0.001), but not in patients 
receiving local therapy alone (A: 74.9–69.5 watts p = 0.06). 
In each cohort, there was no significant change from 6 to 
12 months (A: + 3.4 watts, p = 0.6; B: + 1.4 watts, p = 0.97; 
C: − 1.4 watts, p = 0.76).
In all cohorts, power generation normalized to lean 
mass (watts/kg) dropped at 6 months (Fig. 2), most signifi-
cantly in cohorts B and C (A: 1.89–1.71 watts/kg, p = 0.04; 
B: 1.42–1.04  watts/kg, p = 0.008; C: 1.53–1.18  watts/
kg, p < 0.001). There was no significant change in power/
kg lean mass between 6 and 12  months in any cohort 
(A: 1.71–1.81 watts/kg, p = 0.52; B: 1.04–1.09 watts/kg, 
p = 0.77; C: 1.18–1.18 watts/kg, p = 0.88). For the cohorts 
receiving systemic therapy, the decline in power/kg lean 
mass from baseline to 12 months (Fig. 3) was 19% in the 
endocrine therapy group (cohort B, p = 0.004) and 28% in 
the chemotherapy ± endocrine therapy group (cohort C, 
p < 0.001).
Table 1  Patient demographics 
and disease characteristics of 
study sample
Cohort A
N = 15
Cohort B
N = 33
Cohort C
N = 32
Total
N = 80
Age
(median, range)
57 
(44.8 – 74.1)
57 
(40.2 – 72.6)
49 
(30.2 – 68.1)
55 
(30.2– 74.2)
Race
White
Black
Asian
Other
9
2
0
4
24
7
0
2
22
6
1
3
55 (69%)
15 (19%)
1 (1%)
9 (11%)
Ethnicity
Hispanic
Non-Hispanic
Unknown
0
11
4
1
28
4
2
23
7
3 (4%)
62 (78%)
15 (19%)
Stage
In-situ
I
II
III
3
9
2
1
8
15
9
1
1
11
15
5
12 (15%)
35 (44%)
26 (33%)
7 (9%)
Treatment
Surgery
Radiation
Chemotherapy
Anti-estrogen
15
6
0
0
33
20
0
33
32
18
32
15
80(100%)
44 (55%)
48 (60%)
32 (40%)
Fig. 2  Power generation (watts, normalized to lean body mass) over 
time based on therapy received for early-stage breast cancer, a local 
therapy only; b endocrine therapy as the only systemic therapy; or c 
chemotherapy ± endocrine therapy. The green line represents a “func-
tional norm” of power generation of 2.4 watts/kg lean body mass 
[14]. Power dropped significantly between baseline and 6 months 
in all cohorts (A: p = 0.04, B: p = 0.008, and C: p = < 0.001). * = 
p < 0.05
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Body composition
Body composition, including BMI, lean body mass, body fat 
percentage, and SMI were similar among cohorts at baseline 
(Table 2). Most patients were obese (BMI ≥ 30 kg/m2) at 
study entry and remained obese throughout the study period. 
Mean lean body mass declined significantly over 12 months 
in patients receiving chemotherapy ± anti-estrogen therapy 
(cohort C − 1.5 kg, p = 0.007). Body fat increased signifi-
cantly in patients receiving anti-estrogen therapy alone 
(cohort B + 2.1%, p < 0.001) and in patients receiving 
chemotherapy ± anti-estrogen therapy (cohort C + 2.8%, 
Fig. 3  Percentage change in 
power normalized to lean body 
mass (watts/kg lean mass). 
Overall, from baseline to 
12 months, mean power per kg 
of lean mass decreased by 4.2% 
in cohort A (p = 0.10), 23.2% in 
cohort B (p = 0.004), and 22.9% 
in cohort C (p < 0.001)
-30.0%
-25.0%
-20.0%
-15.0%
-10.0%
-5.0%
0.0%
5.0%
10.0%
Baseline to 6 months 6 to 12 months Baseline to 12 months
Local Therapy
Endocrine Therapy
Chemotherapy
Table 2  Body composition 
changes from diagnosis to 
12 months among early-stage 
breast cancer patients receiving 
localized treatment only (A), 
endocrine therapy (B), or 
chemotherapy ± endocrine 
therapy (C)
Cohort BMI Lean body 
mass (kg)
Body fat (%) Skeletal 
muscle index 
(kg/m2)
A (local)
Baseline
6 months
12 months
p value*
30.6 (5.8)
29.6 (5.9)
30.4 (6.6)
0.65
43.7 (9.3)
40.8 (5.8)
41.2 (6.4)
0.42
46.3 (9.0)
45.5 (10.9)
45.5 (9.8)
0.98
6.83 (0.72)
6.57 (0.65)
6.62 (0.76)
0.63
B (endocrine)
Baseline
6 months
12 months
p value*
30.3 (6.9)
30.4 (6.8)
30.4 (6.8)
0.44
41.6 (5.3)
41.3 (5.5)
41.4 (5.7)
0.68
45.0 (8.1)
46.4 (8.4)
46.9 (7.6)
<0.001
6.75 (0.95)
6.64 (0.96)
6.66 (0.99)
0.38
C (chemotherapy)
Baseline
6 months
12 months
p value*
29.9 (6.1)
30.4 (6.1)
30.6 (6.7)
0.12
41.5 (6.3)
41.3 (6.8)
40.0 (6.4)
0.007
43.2 (9.0)
44.5 (7.6)
46.1 (7.4)
<0.001
6.97 (0.97)
6.96 (0.94)
6.75 (0.94)
0.001
Total
Baseline
6 months
12 months
p value*
30.2 (6.3)
30.3 (6.3)
30.5 (6.6)
0.12
41.9 (6.6)
41.2 (6.0)
40.8 (6.1)
0.04
44.5 (8.6)
45.5 (8.5)
46.3 (7.8)
<0.001
6.85 (0.92)
6.76 (0.91)
6.69 (0.93)
0.003
p values that are significant (p < 0.05) are highlighted in bold
All values expressed as means with (standard deviation)
*p value describes change from baseline to 12 months, < 0.05 is significant
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p < 0.001), but was unchanged in patients receiving local 
therapy alone.
SMI (appendicular lean mass normalized to height) 
declined toward the sarcopenic range in all cohorts and sig-
nificantly decreased in cohort C (mean difference − 0.33 kg, 
p = 0.001) throughout the study period. One patient in cohort 
A was sarcopenic at baseline and subsequently recovered. 
By 6 months, 4 patients in cohort B had developed sarcope-
nia, 2 of whom had persistent sarcopenia at 12 months. One 
patient in cohort C developed sarcopenia at 6 months with 
an additional 2 developing sarcopenia by 12 months.
Correlation between power generation and body 
composition
Finally, we explored the relationship between power char-
acteristics and changes in body composition. In the overall 
study population, we found a significant correlation between 
BMI and power at each time point (baseline r = − 0.25, 
p = 0.03; 6 months r = − 0.31, p = 0.01; 12 months r = − 0.34, 
p = 0.01). Similar findings were seen with body fat percent-
age. Interestingly, there was no correlation between change 
in power and BMI or SMI except for baseline to 6 months 
in cohort B only (Supplemental table 1).
Discussion
Our study found an alarming rate of deconditioning in 
early-stage breast cancer patients at baseline, which only 
worsened following primary therapy and did not improve 
by 12 months after diagnosis. Although the post-treatment 
physical activity trajectories and fitness levels of breast can-
cer patients have been characterized in the control arms of 
exercise intervention studies, these suffer from significant 
selection bias, with the least fit patients unlikely to partici-
pate. Our results better reflect the larger clinical population 
as our patients were not involved in, or interested in, a life-
style intervention [15]. Given the low levels of energetic 
capacity seen in our study, it is unlikely that this popula-
tion would be able to comply with current physical activity 
recommendations. Importantly, our study also documents 
the variability in energetic capacity among our patients, 
highlighting the need for interventions to be personalized in 
order to help patients return to or improve upon pre- treat-
ment fitness levels.
Several other studies examining the “fitness” of breast 
cancer survivors have used different assessments yet reached 
similar conclusions. Jones et al [16] evaluated  VO2 max in 
patients before, during, and after adjuvant therapy, as well 
as in the metastatic setting. They found that breast cancer 
survivors have a  VO2 max similar to someone 20–30 years 
older when compared to population normative data. In 
addition, one-third of patients had a  VO2 max less than the 
threshold for functional independence. The Jones study was 
cross-sectional rather than prospective and did not examine 
the impact of the type of treatment received. Lakoski and 
colleagues examined the time to exhaustion on a treadmill 
in the Cooper Center Longitudinal Study [17], comparing 
the effect of adjuvant therapy in breast cancer patients to 
non-cancer age matched controls. They found that multi-
modality adjuvant therapy (surgery, radiation, and chemo-
therapy) significantly impairs fitness levels. However, in this 
cross-sectional study, patients were an average of 7 years 
from initial diagnosis at the time of evaluation. In addition, 
the effect of endocrine therapy was not assessed. Our study 
is the first to prospectively describe the power generation 
capabilities of early-stage breast cancer patients before and 
after primary therapy, and to evaluate these patients based 
on the treatment modalities received.
The reasons for poor baseline power generation abilities 
seen in our study are likely multi-factorial and vary between 
individual patients. It remains unclear if poor baseline func-
tion is a systemic effect of cancer prior to diagnosis; or 
whether patients who are debilitated, and presumably less 
active, are more likely to develop a clinically apparent can-
cer. Observational evidence suggests that more active indi-
viduals are less likely to be diagnosed with breast cancer [18, 
19]. In our study, we did see a numerically higher baseline 
energetic capacity in the group of patients who required only 
local therapy (cohort A), the majority of whom had stage I 
and presumably less aggressive disease. While this result 
was not statistically significant, it is hypothesis generating.
While skeletal muscle wasting and/or muscle weakness 
has been appreciated in patients with advanced cancer or 
those receiving chemotherapy [12, 20, 21], this phenomenon 
is not well recognized in patients with early-stage disease 
and in those who do not receive chemotherapy. Unexpect-
edly, we saw a very similar trajectory of decline in func-
tion in patients treated with endocrine therapy alone as in 
those treated with chemotherapy. While endocrine-treated 
patients had a decline in function, there was no decline in 
lean body mass, suggesting true muscle dysfunction rather 
than muscle loss. Recent preclinical data have reported that 
maladaptive molecular changes occurring in skeletal muscle 
in response to an increased bone turnover/low estrogen state 
may be responsible for muscle dysfunction independent of 
loss in mass [22, 23].
Seven patients (8.8%) in our study developed frank sarco-
penia during the 12 months following diagnosis. This inci-
dence is lower than described in other studies; for example, 
the incidence of sarcopenia up to 12 months after diagnosis 
in a subset of the observational HEAL study of stage I–IIIA 
breast cancer patients was 15.9% [24]. This difference may 
be due to the inclusion of DCIS and a larger proportion of 
overweight and obese patients in our study. The HEAL study 
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found sarcopenia to be an independent predictor of mortal-
ity, further supporting the need for interventions to address 
muscle loss and dysfunction in this population.
Our study has several limitations. First, results are lim-
ited by a small sample size and a lack of non-breast cancer 
controls. However, the data generated here can be compared 
to population norms and form the basis of future interven-
tional studies. In addition, we did not attempt to isolate the 
effect of specific chemotherapy regimens (anthracyclines vs. 
not) or various endocrine therapies (aromatase inhibitor vs. 
selective estrogen receptor modulator). These deserve more 
detailed examination in the future.
In long-term follow-up of the Women’s Health Initiative 
Study, nearly 75% of post-menopausal women self-reported 
minimal physical activity (< 8 MET h/week) and activity 
levels remained stable over the 8 years of follow-up [25]. 
Together, these data and our results suggest that without 
intervention, the inactive and deconditioned breast cancer 
survivors (the majority of our population) are unlikely to 
improve. The alarming rate of deconditioning at baseline 
in all cohorts points toward the need for interventions in 
the prevention setting, and supports the possible role of 
“pre-habilitation” prior to, or in conjunction with, cancer-
directed therapy. These findings also speak to the need for 
individualized pre- and post-treatment “oncologic rehabili-
tation” programs, similar to cardiac rehabilitation, as a cru-
cial component of cancer survivorship care. To that end, we 
have begun to utilize baseline energy capacity parameters 
from the Power Protocol™ to design individualized physical 
activity recommendations in a currently active clinical trial 
(Individualized Metabolic Rx (iMETx), NCT03158519).
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